Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Must Reads by Date

Must reads for theWeek ending June 3, 2018

Therapy toxicities higher with age in NHL, Tallarico M et al. J Geriatr Oncol. 2018 Apr 16. pii: S1879-4068(18)30131-0.

Waldenström’s macroglobulinemia responds to ibrutinib add-on therapy, Dimopoulos MA, et al. N Engl J Med. 2018 Jun 1. ASCO Abstract 8003.

Lymphoma risk linked to low exercise levels, Etter JL et al. Leuk Res. 2018 Mar 27;69:7-11.

NHL patients over age 65 have more toxicities to novel agents , Tallarico M et al. J Geriatr Oncol. 2018 Apr 16. pii: S1879-4068(18)30131-0

More must reads

Must reads for theWeek ending May 27, 2018

Low exercise levels linked to NHL risk, Etter JL et al. Leuk Res. 2018 Mar 27;69:7-11.

Mantle cell gets no benefit from bortezomib, Romaguera JE et al. Cancer. 2018 May 3. doi: 10.1002/cncr.31361

More must reads

Must reads for theWeek ending May 20, 2018

Investigational Combo for Indolent NHL, Fehniger TA et al. American Association for Cancer Research Annual Meeting, Abstract CT146.

Ibrutinib at 5 years, O’Brien S et al. Blood. 2018;131(17):1910-9.

More must reads

Must reads for theWeek ending May 13, 2018

Kymriah approved for adults with relapsed or refractory large B-cell lymphoma , Novartis press release: Kymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma

Kymriah approved for adults with relapsed or refractory large B-cell lymphoma , Novartis press release: Kymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma

Rituximab plus ALT-803 boosts response in iNHL, Fehniger TA et al. AACR Annual Meeting, Abstract CT146.

More must reads

Must reads for theWeek ending May 6, 2018

5-year results in CLL with ibrutinib, O'Brien S et al. Blood 2018 131:1910-19; doi: https://doi.org/10.1182/blood-2017-10-810044.

Investigational combo active in relapsed/refractory B-cell lymphoma, Phillips T et al. Blood 2018:blood-2017-10-812701; doi: https://doi.org/10.1182/blood-2017-10-812701

More must reads

Pages